August 01, 2025

Dana-Farber Research News 08.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.

Dana-Farber

July 29, 2025

Research Leaders Across New York State Form Empire State Cellular Therapy Consortium

Roswell Park Comprehensive Cancer Center

July 24, 2025

Updates in Systemic Light-Chain Amyloidosis

The ASCO Post

July 24, 2025

Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice

The ASCO Post

July 24, 2025

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

The ASCO Post

July 23, 2025

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

The ASCO Post

Latest Headlines

August 01, 2025

Dana-Farber Research News 08.01.2025

Dana-Farber

July 29, 2025

Research Leaders Across New York State Form Empire State Cellular Therapy Consortium

Roswell Park Comprehensive Cancer Center

July 24, 2025

Updates in Systemic Light-Chain Amyloidosis

The ASCO Post

July 24, 2025

Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice

The ASCO Post

July 24, 2025

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

The ASCO Post

July 23, 2025

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

The ASCO Post

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

Conference Coverage

All Conference News View Conference Calendar

Alzheimer’s Association International Conference (AAIC) 2025

July 29, 2025

Chemo's Impact on Brain Explored

Conexiant

July 28, 2025

Race, Sex, and Steps to Cognition

Conexiant

2025 ASCO Annual Meeting

July 24, 2025

Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice

The ASCO Post

June 02, 2025

Meta-Analysis Reveals How ICIs May Impact Solid Organ Transplant Responses

The ASCO Post

June 05, 2025

Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN

The ASCO Post

EHA 2025 Congress

July 24, 2025

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

The ASCO Post

June 19, 2025

Novel Tri-Specific Antibody Shows Efficacy and Safety in Refractory Myeloma

The ASCO Post

June 19, 2025

Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds

The ASCO Post

Clinical Guidelines

August 01, 2025

Dana-Farber Research News 08.01.2025

Dana-Farber

July 24, 2025

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

The ASCO Post

July 14, 2025

Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models

The ASCO Post

July 14, 2025

Improving Use of Cytomegalovirus Negative and Irradiated Blood Products in an Outpatient Oncology Clinic

JADPRO

Commentary & Perspectives

October 25, 2023

Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way

The ASCO Post

May 04, 2025

Patient and Advanced Practitioner Perspectives on Symptom Burden and Symptom Management in Indolent Systemic Mastocytosis

JADPRO

March 17, 2025

Survivorship and Advance Care Planning in Cancer

JADPRO

January 31, 2024

Generic Drug Shortages and Essential Cancer Medicines

The ASCO Post

FDA & Government News

August 29, 2023

FDA Approves Luspatercept-aamt as First-Line Treatment for Adult Patients With Lower-Risk MDS and Anemia Who May Require Transfusions

The ASCO Post

February 21, 2024

FDA Approves Biweekly Teclistamab Dosing Regimen for Patients With Multiple Myeloma

The ASCO Post

June 21, 2023

FDA Launches Pilot Program to Help Reduce Risks Associated With Using Laboratory Developed Tests to Identify Cancer Biomarkers

The ASCO Post

March 14, 2024

FDA Approves Irinotecan Liposome as First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

The ASCO Post

Trending Now

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

KFF Health News

Conexiant

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

The New Optometrist

The Pathologist

Reuters

Plenary Highlights Across Tumor Types Reflect Advances in Research, Improvements in Care, and Changes in Practice

Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL

Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML

Latest Headlines

Daily News

Recommendations

Conference Coverage

Alzheimer’s Association International Conference (AAIC) 2025

2025 ASCO Annual Meeting

EHA 2025 Congress

Clinical Guidelines

Commentary & Perspectives

FDA & Government News